首页 > 文献资料
-
AIM To study the effects of ATRA on experimental liver metastasis of gastric cancer cells.METHODS MGc80-3 and SGC-7901 cells were injectied into spleen subcapsule of nude mice, who weresubsequently administrated with ATRA every other day. Food-intake and body weight of mice were measuredweekly. After six weeks, the nude mice were executed, tumors in spleen and liver were examinedpathologically, microtumor vessel density (MVD) was accounted by immunohistochemical method and serumCEA was measured by radioimmunoassay.RESULTS Nude mice administrated with ATRA, the growth of spleen tumor and its metastatic ability toliver were inhibited, the metastatic rate was decreased by 33.3% (MGc80-3) and 50.0% (SGC-7901). SpleenMVD and liver MVD were reduced by 28.6% and 22.9% (MGc80-3), 23.7% and 37.6% (SGC-7901),respectively. The serum CEA was lowered by 43.4% (MGc80-3).CONCLUSION ATRA can effectively inhibit the experimental liver metastasis of gastric cancer cells,which is relavant with the decrease of MVD and CEA.
-
结直肠癌肝转移治疗进展
结直肠癌( colorectal carcinoma ,CRC)是当今世界发病率第三位、导致人类死亡第四位的恶性肿瘤[1],且发病率和死亡率在世界范围内迅速上升[2]。肿瘤远处转移是影响CRC预后的重要因素,肝转移尤甚,约有40%~50%的CRC患者死于肝转移[3],包括同时性肝转移和延迟性肝转移。目前,以外科手术治疗占绝对主导地位的多学科协作诊疗方式日益受到重视,普及应用,且受益良多。新辅助化疗、辅助化疗、介入化疗、分子靶向治疗和肝转移灶局部治疗等治疗方法的应用,大大提高了手术治疗的切除率及患者的生存期。本文就结直肠癌肝转移( colorectal cancer liver metastasis , CRLM)的综合治疗相关热点进行阐述。
-
结直肠癌肝转移的治疗新策略--一场无硝烟的持久战
一、结直肠癌肝转移的现状和思考-初探战场
(一)结直肠癌肝转移的发病现状与特点-难以攻克的“碉堡”
结直肠癌( colorectal cancer , CRC )仍然是人类常见的恶性肿瘤之一,据统计,2010年全球新发病例约为120万例,居恶性肿瘤第三位;而同年死亡60.8万例,仍是人类健康的重大威胁[1];初次接诊时大约有20%~25%的新病例为已经伴有结直肠癌肝转移(colorectal liver metastasis,CLMs),而那些接受根治性治疗的患者,将有大约三分之一的病例终会出现疾病转移、复发而成为晚期[2],即在所有CRC中大约50%的患者终属于 CLMs;可见CLMs是一个庞大的群体,由于转移复发的程度、范围和累及的器官不同, CLMs的预后、治疗目的和手段也表现各异。面对这一威胁人类健康的巨大病魔,人类发起了一场全球性攻克CLMs的持久战役。 -
老年男性胃癌肝转移术后尿少及双下肢重度浮肿1例
1病例摘要患者男性,67岁,主因"发现双下肢水肿3d"于2008年2月10日入院治疗.
-
眼睛葡萄膜恶性黑色素瘤肝转移的外科治疗
眼睛葡萄膜恶性黑色素瘤由葡萄膜黑色素细胞发育来,常见的转移部位为肝脏,葡萄膜恶性黑色素瘤40%~80 9/6的病人有肝脏转移[1,2].过去认为恶性黑色素瘤病人肝转移为Ⅳ期病人,不适合手术切除.
-
3TSR对裸鼠胰腺癌肝转移抑制作用的实验研究
胰腺癌是常见的消化系统肿瘤,由于胰腺位于腹膜后,位置深,80%以上的胰腺癌患者在确诊时已经存在广泛的局部侵犯及淋巴、血行转移,其中半数以上为肝转移[1-2].因此,迫切需要可应用于临床的能抑制胰腺癌生长并阻断其转移的药物以改善患者的预后.近年来,随着血管生成抑制剂研究的深入,抗血管生成治疗为肿瘤治疗开辟了一条新的途径.3TSR(three hrombospondin-1 type 1 repeats)是早发现的抗新生血管形成和抑制肿瘤生长药物TSP-1(Thrombspondin-1)的功能结构域,具有与TSP-1相似的抗新生血管形成作用而其他作用少,我们初步研究表明3TSR具有明显的抗肿瘤作用[34].本研究利用TSP-1的抗新生血管形成的结构功能域3TSR,探讨其单用或合用健择(gemza)对裸鼠胰腺癌肝转移的影响,为临床应用提供依据.
-
结肠癌肝尾状叶转移病人肝切除的预后
肝尾状叶孤立转移病人的预后仍不是很明确.该研究分析了结肠癌肝尾状叶孤立转移灶切除病人的预后.作者回顾了114例可能治愈的结肠癌孤立肝转移灶肝切除病人的资料.
-
我国结直肠癌肝转移外科治疗的现状
结直肠癌是我国常见的肿瘤之一,肝脏是其常见的转移部位,结直肠癌原发灶切除后60%的患者会发生肝转移.手术是惟一可能治愈结直肠癌肝转移(colorectal cancer liver metastasis,CRLM)的方法.
-
肝转移灶无法切除时结直肠癌原发灶的治疗策略
结直肠癌是人类常见的恶性肿瘤之一,全球每年结直肠癌新发病例120 万,死亡病例超过60 万[1].在中国,结直肠癌发病率呈逐渐上升趋势,发病率每年递增速度快于全球年均递增速度[2]. 结直肠癌肝转移(colorectal liver metastasis,CRLM)是结直肠癌治疗的难点问题,也是其主要的死亡原因[3]. 文献报道,15℅ ~25℅的结直肠癌患者在明确诊断时即有CRLM(同时性肝转移) ,另有15℅ ~40℅在原发灶治疗后出现CRLM (异时性肝转移) [3]. 手术切除是根治CRLM的有效手段,然而,初次评估时, 80℅ ~90℅CRLM无法手术切除[4-6].
-
结直肠癌肝转移的治疗策略
结直肠癌又称大肠癌,在西方国家占肿瘤死亡的第2位,发病率为56.1/10万.我国结直肠癌发病率约为 20.6/10万,占肿瘤死亡的第5位.肝转移是结直肠癌主要的死亡原因之一,约有50%的结直肠癌终发生肝转移.
-
Objective To evaluate the toxic effects and efficacy of the intra-arterial chrono-chemotherapy on patients with liver metastasis arised from colorectal cancer. Methods Chemotherapy of 42 patients were randomly divided into group A (n = 20) with continuously constant arterial infusion, and group B (n = 22) with arterial chrono-modulated infusion. And the toxic effects and efficacy of two groups were compared. Results A significant difference was found in the toxic effects of digestive system between the two groups. The treatment response was similar in the two groups. Conclusions Intra-arterial chrono-chemotherapy may decrease the toxic effects and improve the life quality of these patients.
-
Cystic liver metastasis, which lacks specific clinical manifestations and standardized treatment, rarely occurs after radical gastrectomy. This study presented two gastric cancer cases with cystic liver metastasis treated in Wuxi People’s Hospital from September 2008 to November 2012. The two female patients were 66 and 65 years old, respectively. Poorly dif erentiated ulcerated adenocarcinoma classified as stage III B [Tumor, Node, and Metastasis Classification (T4aN2M0)] and clinical manifestations of abdominal distension and ascites were detected in both patients. Cyst fluids were subjected to cy-tological analysis. Results confirmed the presence of liver metastasis of gastric cancer. The two patients benefited from local intracavitary chemotherapy or systemic intravenous chemotherapy.
-
努力提高结直肠癌肝转移的切除率
肝脏是结直肠癌转移常见的靶器官.25%~30%的结直肠癌患者伴同时性肝转移,50%~75%的患者在结直肠癌晚期发生肝转移,并因此而死亡.结直肠癌肝转移(eolorectal cancer liver metastasis,CRLM)约占Ⅳ期结直肠癌的60%,不少国家将其作为一个单独疾病来对待.如欧洲成立了结直肠转移治疗组(European Colorectal Metastases Treatment Group,ECMTG)并制定了关于CRLM的共识:英国、加拿大、西班牙均对此有专家共识.
-
胃癌肝转移的特点及其外科治疗新理念
20世纪70年代前.实体癌肝转移均被认为是姑息治疗的对象;80年代以后,一些学者相继报道结直肠癌肝转移行肝切除是一种有效的治疗方法.近年来.结直肠癌肝转移的外科治疗已取得良好的效果.然而,胃癌肝转移外科治疗效果仍不理想.
-
无功能胰岛细胞瘤复发伴肝转移1例
患者男,75岁,发现左上腹肿块增大1月余,门诊收治入院.查体:肿块大小约7 cm,不规则,边缘不光整,质地硬,推移略有活动.自述无明显不适.入院血常规及生化检查均正常.既往11年前曾行胰尾肿瘤手术,肿瘤巨大,切下重约8 kg.手术病理:无功能胰岛细胞瘤恶变,胰尾肿瘤切除,脾切除.